OICR News / Tag

Centre for Probe Development and Commercialization

Browse news tagged Centre for Probe Development and Commercialization.

Browse all news

Filters

Discover the latest news and insightsDiscover the latest news and insights

All Collaboration Commercialization Talent Technology

All Video Article

Tagged stories

Commercialization

OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion

This landmark acquisition of the Hamilton-based company comes after years of funding and support from OICR and FACIT. AstraZeneca’s acquisition of Hamilton-based Fusion Pharmaceuticals for up to US $2.4 billion marks a major milestone for…

ArticleMar 25, 2024

CommercializationTreatment

New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals

AtomVie Global Radiopharma is the latest company launched by the OICR-supported centre The Centre for Probe Development and Commercialization’s (CPDC) newest spinout company has now launched as AtomVie Global Radiopharma Inc. On August 24, the…

ArticleSep 14, 2022

Commercialization

Ontario centre attracts national attention for probe research, development and commercialization

The Centre for Probe Development and Commercialization (CPDC) awarded $10.5 million to expand molecular imaging probe work in Ontario Translating new scientific discoveries into products and moving those products to the market is a challenging…

ArticleAug 02, 2018

Commercialization

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations TORONTO, ON (September 25, 2017) – Ontario oncology innovations investor FACIT congratulates Fusion Pharmaceuticals (“Fusion”), a developer of novel targeted alpha particle radiotherapies,…

ArticleOct 04, 2017

Commercialization

FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products TORONTO, ON (February 23, 2017) – The Fight Against Cancer Innovation Trust (FACIT) and the Ontario Institute for Cancer Research (OICR) are pleased to report…

ArticleFeb 23, 2017

Commercialization

From our Annual Report: Investing in the cure and the economy

Ontario has some of the finest cancer researchers in the world who are developing new cancer therapies, diagnostic tools and other anti-cancer technologies. When these novel products make their way into clinical use they improve…

ArticleOct 05, 2016

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Centre for Probe Development and Commercialization

Discover the latest news and insightsDiscover the latest news and insights

Tagged stories

OICR-supported cancer therapeutics company Fusion Pharmaceuticals acquired by AstraZeneca for up to US $2.4 billion

New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals

Ontario centre attracts national attention for probe research, development and commercialization

Cancer solved together — in your inbox

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

From our Annual Report: Investing in the cure and the economy